Nyse Order Imbalance 11953.0 Shares On Sell Side

Investing.com – Canada stocks were higher after the close on Monday, as gains in the Healthcare, Materials and IT sectors led shares higher.

At the close in Toronto, the S&P/TSX Composite added 0.80% to hit a new all time high.

The best performers of the session on the S&P/TSX Composite were Aya Gold & Silver Inc (TSX:AYA), which rose 12.02% or 2.57 points to trade at 23.95 at the close. Meanwhile, Curaleaf Holdings Inc (TSX:CURA) added 8.00% or 0.28 points to end at 3.78 and Bitfarms Ltd (TSX:BITF) was up 7.95% or 0.31 points to 4.21 in late trade.

The worst performers of the session were Emera Incorporated (TSX:EMA), which fell 2.40% or 1.63 points to trade at 66.36 at the close. Exchange Income Corporation (TSX:EIF) declined 2.22% or 1.97 points to end at 86.74 and Gildan Activewear Inc. (TSX:GIL) was down 2.14% or 1.89 points to 86.45.

Rising stocks outnumbered declining ones on the Toronto Stock Exchange by 639 to 354 and 67 ended unchanged.

Shares in Aya Gold & Silver Inc (TSX:AYA) rose to all time highs; up 12.02% or 2.57 to 23.95.

The S&P/TSX 60 VIX, which measures the implied volatility of S&P/TSX Composite options, was up 4.54% to 12.66.

Gold Futures for February delivery was up 2.28% or 102.74 to $4,603.64 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in March rose 1.15% or 0.68 to hit $59.62 a barrel, while the March Brent oil contract rose 1.03% or 0.65 to trade at $63.99 a barrel.

CAD/USD was unchanged 0.26% to 0.72, while CAD/EUR unchanged 0.01% to 0.62.

The US Dollar Index Futures was down 0.23% at 98.67.

Investing.com -- Zenas BioPharma (NASDAQ:ZBIO) stock fell 50% despite the company announcing results from its Phase 3 INDIGO trial for obexelimab in treating Immunoglobulin G4-Related Disease (IgG4-RD).

The clinical-stage biopharmaceutical company reported that obexelimab met its primary endpoint, demonstrating a 56% reduction in the risk of IgG4-RD flare compared to placebo during the 52-week randomized placebo-controlled period. The drug also achieved statistically significant results across all four key secondary endpoints.

Despite these seemingly positive results, investors reacted negatively to the news. The sharp decline in share price suggests the market may have expected even stronger efficacy data or could be concerned about the extended timeline for regulatory submissions, with the company planning to file with the FDA in the second quarter of 2026.

Zenas indicated that obexelimab was well tolerated in the trial, with rates of infections lower in the treatment arm compared to placebo. The company views the drug as a potential first-line therapy for IgG4-RD, highlighting its at-home subcutaneous self-administration as a key advantage.

"We look forward to submitting our Biologics License Application to the FDA in the second quarter of 2026 and our Marketing Authorization Application to the EMA in the second half of this year," said Lonnie Moulder, Founder and CEO of Zenas.

The company is also advancing obexelimab in a Phase 2 trial for Systemic Lupus Erythematosus, with results expected later this year. Additionally, Zenas is developing orelabrutinib for multiple sclerosis and plans to initiate Phase 1 trials for two other drug candidates in 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Theriva Biologics Inc (NYSE American:TOVX) stock surged 25.4% in Monday premarket trading after the company announced receiving positive scientific advice from the European Medicines Agency (EMA) regarding its proposed Phase 3 clinical trial design for VCN-01 in pancreatic cancer treatment.

The EMA’s Committee for Medicinal Products for Human Use (CHMP) provided overall agreement with Theriva’s proposed pivotal trial of VCN-01 in combination with standard chemotherapy for first-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC). The regulatory body endorsed key elements including sample size, repeated dosing of VCN-01, and an adaptive design approach.

Importantly, the EMA recognized the improved survival outcomes observed in patients who received multiple doses of VCN-01 in earlier trials and agreed with Theriva’s proposed "macrocycle" dosing regimen that would allow for more than two doses in the Phase 3 trial.

"We are very encouraged by the scientific advice we received from the EMA regarding our proposed pivotal Phase 3 trial of VCN-01 plus gemcitabine/nab-paclitaxel SoC in metastatic PDAC patients," said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.

The company plans to schedule an End-of-Phase 2 meeting with the FDA in the first half of 2026 to finalize the protocol for a multinational Phase 3 trial. Theriva is also seeking regulatory advice on a potential Phase 2/3 trial for VCN-01 in retinoblastoma, a rare childhood cancer.

Theriva reported having $15.5 million in cash and equivalents as of November 10, 2025, providing runway into the first quarter of 2027 as it completes regulatory interactions and pursues partnerships to support manufacturing scale-up and conduct of proposed pivotal trials.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.